SR One is GlaxoSmithKline’s independent corporate healthcare venture capital fund.
SR One is a venture capital fund that invests globally in emerging biotech companies that are focused on drug discovery, development or delivery and have the potential to make products that will have a dramatic benefit to patients.
They have a Team of seven investment professionals, located in the US and UK. As a Team, their experience spans basic science, industry and the market.
They take an active role in their portfolio companies and work with management teams and their fellow venture capital investors to create significant value. Their current portfolio includes more than 30 private and public companies and since their founding in 1985, they have invested over $500MM in the biotech space.
SR One invests globally in emerging biotech companies that are focused on drug discovery, development or delivery and have the potential to make products that can have a dramatic benefit to patients. They are interested in companies with products that are in preclinical development through clinical proof-of-concept. Overall, they look for investments that can provide attractive financial returns and significant strategic value.
They have a Team of seven investment professionals that serve as the Fund’s managers and Investment Committee. They understand the challenges facing emerging companies. Together, they bring practical industry expertise, an operational orientation and long-term perspective, from the beginning of the investment process through all aspects of value creation. Their investment record and focus on returns aligns them with financial investors and their industry perspective positions them to work effectively with company management teams.
They lead investments and work with other financial or strategic investors to syndicate their deals. They will also actively participate in opportunities as part of a syndicate. They are aligned with other financial investors and do not ask for specific product rights or options. They are active investors and typically take board of directors or board observer seats. They also maintain a strict firewall with GlaxoSmithKline (GSK) on confidential items received from a portfolio company or an investment opportunity under review by their team.
SR One is structured as an evergreen fund. They place approximately $25-50MM each year, including follow-on investments in their portfolio companies. They invest between $500K and $5MM in each round of financing.
For more information on SR One, please visit the company website.
